# **Special Issue**

# **Exploring Uric Acid and Beyond**

## Message from the Guest Editors

Serum uric acid (UA) is a clear and an independent predictor of all-cause and cardiovascular mortality but also acute coronary syndrome, stroke, and heart failure. Moreover, a high UA level is a risk factor for the new onset and progression of chronic kidney disease (CKD). In the CKD field, the new therapeutic era of the sGLT2i, with its uricosuric effects, has allowed new stimulating research inputs into the management of the UA-CKD interplay. New and interesting insights into the correlation between hyperuricemia and metabolic derangement have been emerging from extended research papers that have clarified that the UA is a causative pathologic element of metabolic syndrome. diabetes, obesity, and dyslipidemia. The relationship between hyperuricemia and the immune system, with its role as a danger signal in immunity and inflammation, has been a growing research interest for our and other working groups. The aim of this Special Issue is to review the role of UA as a global risk factor in medicine. with particular attention to special subgroup populations, i.e., CKD, obese, and diabetic patients.

#### **Guest Editors**

Dr. Pietro Cirillo


 Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, 70122 Bari, Italy
 Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy

### Prof. Dr. Claudio Borghi

Atherosclerosis and Metabolic Disease Study Center, University of Bologna, 40138 Bologna, Italy

## Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/196344

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





# Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

### Editor-in-Chief

#### Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

